At a glance
ClinicalIndex Comparison Record- ✓Age 18 years or older
- ✓Behçet's disease without refractory life/organ/sight-threatening symptoms with active disease (BDCAF >2 new or >15 old, or clinical grounds)
- ✓Dermatomyositis per European Neuromuscular Centre 2018 guidelines with active disease (CDASI ≥5, elevated muscle enzymes, MRI evidence, or clinical grounds)
- ✓Anti-synthetase syndrome per European Neuromuscular Centre 2003 guidelines with active disease (CDASI ≥5, elevated muscle enzymes, MRI evidence, or clinical grounds)
- ✕Age <18 years
- ✕Age ≥65 years
- ✕Life expectancy less than 6 months
- ✕Juvenile dermatomyositis, myositis overlapping with other autoimmune diseases, IMNM, inclusion-body myositis, or cancer-associated myositis
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
In Brief
A Phase 2 clinical trial evaluating Filgotinib for Behcet's Disease and 2 related conditions. Currently recruiting, targeting 60 participants across 6 sites.
Detailed Summary
Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations. Patients with Behçet's disease (BD), idiopathic inflammatory myopathy (IIM, also known as myositis) and IgG4-related disease (IgG4-RD) are treated with high-dosed glucocorticoids, methotrexate, azathioprine and mycophenolate mofetil, mostly for long periods of time with attendant risks of long-term toxicity, including infections. Therefore, there is an urgent need for new, more specific anti-inflammatory therapies such as targeted synthetic and biological disease-modifying antirheumatic drugs. Due to the role of type 1 interferon in both BD, IIM and IgG4-RD, JAK-STAT inhibition may be a promising treatment strategy in these conditions, because JAK1 is critical for the signal transduction of pro-inflammatory cytokine receptors. Previous research showed that JAK1 inhibition reduces activation of type 1 interferon-regulated proteins and key chemokines that control tissue inflammation.
Study Details
Timeline
Interventions
Filgotinib